Regression of Myocardial Fibrosis After Aortic Valve Replacement
Launched by UNIVERSITY COLLEGE, LONDON · Jun 24, 2014
Trial Information
Current as of June 17, 2025
Completed
Keywords
ClinConnect Summary
Surgery for severe aortic stenosis (AS) prior to symptom onset is controversial. Conventionally changes in valve area and gradient are used to time intervention but myocardial changes may be more predictive of surgical need. This study aims to elucidate the role of diffuse myocardial fibrosis as a prognostic marker, implementing a novel, non-invasive technique to measure it.
AS is the most common valvular heart condition in the United Kingdom and the Western world. Its prevalence rises with age - about 3% aged over 75 have severe AS. During a period of progressive valve narrowing, the left...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Severe aortic stenosis (1 or more of: aortic valve area \< 1.0cm2, peak pressure gradient \>64mmHg, or mean pressure gradient \> 40mmHg).
- • Symptomatic.
- • Age \> 18 years and \< 90 years.
- Exclusion Criteria:
- • Severe valvular disease other than AS.
- • Previous Valve surgery
- • Severe renal impairment eGFR \< 30ml/min.
- • Any absolute contraindication to CMR
- • Other medical condition that limits life expectancy or precludes AVR.
- • Pregnancy
About University College, London
University College London (UCL) is a leading global research institution renowned for its commitment to advancing healthcare through innovative clinical trials. As a prominent sponsor of clinical research, UCL leverages its multidisciplinary expertise and state-of-the-art facilities to conduct rigorous investigations aimed at improving patient outcomes and addressing pressing medical challenges. The institution fosters collaboration among researchers, healthcare professionals, and industry partners, ensuring that its trials adhere to the highest ethical standards and regulatory guidelines. UCL's dedication to translating scientific discoveries into practical applications underscores its role as a vital contributor to the advancement of medical science and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
London, , United Kingdom
Patients applied
Trial Officials
James C Moon, MD
Principal Investigator
University College, London
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials